Abstract:DNA damage is a key factor both in the evolution and treatment of cancer Genomic instability is a common feature of cancer cells, fuelling accumulation of oncogenic mutations while radiation and diverse genotoxic agents remain important, if Imperfect, therapeutic modalities Cellular responses to DNA damage are coordinated primarily by two distinct kinase signaling cascades, the ATM-Chk2 and ATR-Chk1 pathways, which are activated by DNA double strand breaks (DSBs) and single stranded DNA respectively Historically these pathways were thought to act in parallel with overlapping functions, however, more recently It has become apparent that their relationship is more complex In response to DSBs, ATM is required both for ATR-Chk1 activation and to inmate DNA repair via homologous recombination (HRR) by promoting formation of single stranded DNA at sites of damage through nucleolytic resection Interestingly cells and organisms survive with mutations in ATM or other components required for HRR, such as BRCA1 and BRCA2 but at the cost of genomic instability and cancer predisposition By contrast the ATR-Chk1 pathway is the principal direct effector of the DNA damage and replication checkpoints and, as such, is essential for the survival of many, although not all, cell types Remarkably, deficiency for HRR in BRCA1 and BRCA2 deficient tumors confers sensitivity to cisplatin and inhibitors of poly(ADP ribose) polymerase (PARP), an enzyme required for repair of endogenous DNA damage In addition, suppressing DNA damage and replication checkpoint responses by inhibiting Chk1 can enhance tumor cell killing by diverse genotoxic agents Here, we review current understanding of the organization and functions of the ATM-Chk2 and ATR-Chk1 pathways and the prospects for targeting DNA damage signaling processes for therapeutic purposes (C) 2010 Elsevier Inc

Targeting DNA checkpoint kinases in cancer therapy.

Drug Discovery Targeting Chk1 and Chk2 Kinases.

Targeting the DNA Repair Pathway for Breast Cancer Therapy: Beyond the Molecular Subtypes.

DNA damage checkpoint kinases in cancer

Targeting Chk2 Kinase: Molecular Interaction Maps and Therapeutic Rationale

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Targeting the checkpoint kinases: chemosensitization versus chemoprotection

The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.

Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair

Functions and Inhibitors of CHK1 in Cancer Therapy

ATM, ATR and DNA Damage-Induced Cell Cycle Arrest

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications

Targeting DNA damage response pathways in cancer

Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategies

DNA Damage Checkpoint Recovery and Cancer Development

DNA-PK as an Emerging Therapeutic Target in Cancer

Targeting replication stress in cancer therapy

The DNA damage response: putting checkpoints in perspective

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy

Targeting DNA Repair Pathways: Mechanisms and Potential Applications in Cancer Therapy

Development and therapeutic potential of DNA-dependent protein kinase inhibitors